Diagnosis of non‐follicular Lymphoma (ICD‐10 C83) was confirmed in 2,178 patients, DLBCL (ICD‐10 C83.3) in 819 patients. The analysis was age‐ and gender‐adjusted, observational period was 2014 and 2015. Treatments were analyzed for hospitalization and medication based on ATC code, ...
In support of this data suggesting the importance of B cells in a successful anti-cancer immune response, long-term follow-up of CD20 depletion with Rituximab in patients with lymphoma, it was shown that CD20 depletion was an independent risk factor for the development of secondary solid tumour...
Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and autoimmune disease. However, the cellular and molecular pathways for B cell ... Uchida,J. - 《Journal of Experimental Medicine》 被引量: 1291发表: 2004年 A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype...
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituxima... PURPOSE: The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage ...
the presence of IL-10-producing Bregs was shown to inhibit the therapeutic efficacy of the humanized anti-CD20 antibody rituximab, which has proven to be effective in the treatment of non-Hodgkin lymphoma and CLL through B-cell depletion.91Since Bregs express low levels of CD20, CD20-depletion...
Furthermore, patients with a previous diagnosis of HIV infection any time prior to their first DLBCL diagnosis or lymphoma more than a year prior to their first DLBCL diagnosis (defined as ICD-9 histology codes: 9590–9769) were excluded. Further details are reported elsewhere [8]. Outcomes ...
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
Here, we show that FGF4 produced by B cell lymphoma cells (LCs) through activating FGFR1 upregulates the Notch ligand Jagged1 (Jag1) on neighboring ECs. In turn, upregulation of Jag1 on ECs reciprocally induces Notch2-Hey1 in LCs. This crosstalk enforces aggressive CD44+IGF1R+CSF1R+ LC...
Moreover, dysregulation of the NF-κB pathway can contribute to B-cell lymphomagenesis8,9. A hallmark of the activated B-cell subtype of diffuse large B-cell lym- phoma (ABC-DLBCL) is constitutive NF-κB activation due to chronic active BCR signaling10. B-cell lymphomas in which ...
Epstein-Barr Virus-Transformed B-Cell Line (DV-1) Derived from Bone Marrow of a Patient with Severe Combined Immunodeficiency and Immunoblastic Lymphoma HOWARD M. ROSENBLATT, DOROTHY E. LEWIS, JEFFREY SKLAR, MICHAEL L. CLEARY, NIRMI PARIKH, NAOMI GALILI, JEROME RITZ, AND WILLIAM T. SHEARER ...